company background image
FSTX

F-star Therapeutics NasdaqCM:FSTX Stock Report

Last Price

US$5.32

Market Cap

US$116.9m

7D

-5.3%

1Y

4.1%

Updated

08 Dec, 2022

Data

Company Financials +
FSTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

FSTX Stock Overview

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy.

F-star Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for F-star Therapeutics
Historical stock prices
Current Share PriceUS$5.32
52 Week HighUS$6.76
52 Week LowUS$2.07
Beta0.16
1 Month Change8.79%
3 Month Change-18.03%
1 Year Change4.11%
3 Year Changen/a
5 Year Changen/a
Change since IPO31.03%

Recent News & Updates

F-star Therapeutics: Running Into A National Security Roadblock

Sep 22

F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale

Sep 15

Recent updates

Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues

May 18
Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues

US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results

Mar 17
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results

These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts

Mar 16
These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts

Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like

Mar 17
Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like

Shareholder Returns

FSTXUS BiotechsUS Market
7D-5.3%0.5%-2.8%
1Y4.1%-8.6%-19.6%

Return vs Industry: FSTX exceeded the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: FSTX exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is FSTX's price volatile compared to industry and market?
FSTX volatility
FSTX Average Weekly Movement10.3%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: FSTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: FSTX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200286Eliot Forsterhttps://www.f-star.com

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

F-star Therapeutics, Inc. Fundamentals Summary

How do F-star Therapeutics's earnings and revenue compare to its market cap?
FSTX fundamental statistics
Market CapUS$116.94m
Earnings (TTM)-US$44.75m
Revenue (TTM)US$21.18m

5.5x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FSTX income statement (TTM)
RevenueUS$21.18m
Cost of RevenueUS$0
Gross ProfitUS$21.18m
Other ExpensesUS$65.92m
Earnings-US$44.75m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.04
Gross Margin100.00%
Net Profit Margin-211.32%
Debt/Equity Ratio17.3%

How did FSTX perform over the long term?

See historical performance and comparison